NASDAQ · CAI
Healthcare · Biotechnology
$24.43
Down-$1.14 (-4.46%)
Updated Nov 11, 2026, 1:32 PM
SID Score
5.3/10
Composite research score
Smart Money
58/100
Neutral
Price performance · CAI
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 10, 2026
CAI closed at $24.43 after 21 trading sessions, down 17.27% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 10, 2026 | $25.80 | $25.80 | $23.90 | $24.43 | 5.07M |
| Nov 9, 2026 | $25.29 | $26.015 | $24.60 | $25.57 | 4.9M |
| Nov 6, 2026 | $26.41 | $26.57 | $24.09 | $25.23 | 10.29M |
| Nov 5, 2026 | $27.18 | $27.76 | $25.30 | $26.03 | 7.83M |
| Nov 4, 2026 | $33.51 | $34.10 | $31.88 | $33.22 | 4.09M |
| Nov 3, 2026 | $32.27 | $34.00 | $32.14 | $32.85 | 2.68M |
| Nov 2, 2026 | $34.945 | $35.052 | $32.03 | $32.10 | 3.26M |
| Oct 30, 2026 | $35.30 | $35.7096 | $33.71 | $34.33 | 3.67M |
| Oct 29, 2026 | $35.73 | $36.24 | $34.872 | $36.14 | 3.79M |
| Oct 28, 2026 | $33.52 | $36.50 | $33.49 | $35.45 | 4.25M |
| Oct 27, 2026 | $32.40 | $34.06 | $32.0703 | $33.67 | 3.38M |
| Oct 26, 2026 | $32.00 | $32.57 | $31.75 | $32.455 | 2M |
| Oct 23, 2026 | $31.74 | $32.16 | $30.95 | $32.00 | 2.32M |
| Oct 22, 2026 | $32.00 | $32.61 | $30.33 | $31.71 | 2.42M |
| Oct 21, 2026 | $31.11 | $32.75 | $30.925 | $32.35 | 2.23M |
| Oct 20, 2026 | $30.71 | $31.56 | $30.10 | $31.11 | 3.54M |
| Oct 19, 2026 | $31.26 | $31.99 | $30.62 | $30.71 | 2.1M |
| Oct 16, 2026 | $31.76 | $32.40 | $30.155 | $30.56 | 2.73M |
| Oct 15, 2026 | $29.50 | $32.15 | $28.80 | $31.76 | 3.55M |
| Oct 14, 2026 | $29.23 | $31.53 | $29.0225 | $30.255 | 4.35M |
| Oct 13, 2026 | $29.48 | $29.78 | $28.665 | $29.53 | 3.52M |
The latest Smart Investors Daily articles mentioning CAI.
Company
Market Activity
Research & News
CAI research
Company profile and research snapshot.
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 10, 2026 | Piper Sandler | Neutral | — |
| Nov 6, 2026 | Citigroup | Buy | — |
| Nov 5, 2026 | TD Cowen | Buy | — |
| Nov 5, 2026 | BTIG | Buy | — |
| Oct 27, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
Yahoo · Nov 7, 2026
Caris Life Sciences Inc (CAI) posted 27% revenue growth to a record $275.4 million, returned to GAAP profitability, and lifted its 2026 revenue outlook to roughly $1.04 billion to $1.05 billion.
Benzinga · Nov 6, 2026
Citigroup analyst Albert Hu maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $28 to $36.
Benzinga · Nov 5, 2026
TD Cowen analyst Dan Brennan maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $36 to $38.
Yahoo · Nov 5, 2026
Clinical volume surged while capacity constraints remain a watch point.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CAI.
